Novogen is developing new


therapies for cancer that have the potential to make a significant impact

Novogen is a global biotechnology company dedicated to creating sustainable long-term shareholder value through the discovery and development of signifcant new therapies for patients with cancer.

  • News

    26 October 2016New

    Novogen presents at AusBiotech ConferenceRead more

    19 October 2016New

    Annual Report for the year ended 30 June 2016Read more

    17 October 2016New

    Notice of Annual General MeetingRead more

    More News

  • Upcoming Events

    7 NOVEMBER 2016

    RACI Medicinal Chemistry and Chemical Biology Conference 2016 in Coogee, New South Wales

    Dr Eleanor Eiffe, Drug Discovery Program Manager, will present on Anisina.

    14-16 NOVEMBER 2016

    World Pre-clinical Congress in Lisbon, Portugal

    Dr Eleanor Eiffe is presenting a Poster on Cantrixil Chemistry.

    29 November - 2 December 2016

    EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium in Munich, Germany

    Dr Justine Stehn, ATM Program at Novogen Limited, will present a poster on Anisina.

    More Events

  • Scientific Advisory Board

    Novogen appoints an international Scientific Advisory Board of oncology experts

    Read more

  • Share Price

    Historical Prices